Talphera Inc Dossier - Source-backed chat

Talphera Inc

TLPHNASDAQ

SectorHealth Care

IndustryPharmaceuticals

Beta (adjusted)0.81

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.12Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $58.1M

Enterprise Value $57.4M

Shares Outstanding 51.9M diluted

Next Earnings Date11 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Talphera, Inc. is a clinical-stage specialty pharmaceutical company focused on developing innovative therapies for medically supervised settings. The primary investment thesis centers on its lead product candidate, Niyad® (a lyophilized formulation of nafamostat), which is currently in a Phase 3 registrational study (NEPHRO CRRT) as a regional anticoagulant for the extracorporeal circuit in Continuous Renal Replacement Therapy (CRRT). Niyad has received Breakthrough Device Designation from the FDA. With 50% enrollment achieved in March 2026 and study completion expected later in 2026, the company is well-positioned to address a significant unmet medical need in the US, where no FDA-approved regional anticoagulants currently exist for CRRT. A strategic minority equity investment of $5 million by CorMedix Inc. in September 2025, which includes a 60-day exclusive right of first negotiation for acquisition post-Phase 3 data, provides strong validation and a potential exit pathway for investors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.17

High · most bullish analyst$3.50

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5010%

The NEPHRO CRRT study experiences enrollment delays or fails to meet its primary safety/efficacy endpoints. The FDA requests additional clinical trials, delaying or preventing PMA approval. The company runs out of cash before achieving regulatory milestones, leading to highly dilutive equity raises or insolvency, and CorMedix declines to acquire the company.

Base CaseCentral scenario

$3.0060%

The NEPHRO CRRT study completes in late 2026 with positive top-line results. Talphera utilizes its remaining conditional financing tranches ($16 million) to fund operations through the PMA submission and potential approval in 2027. CorMedix engages in acquisition negotiations, or Talphera secures a commercialization partner for Niyad. Stock price converges toward the consensus analyst target.

Bull CaseUpside scenario

$3.5030%

The NEPHRO CRRT study completes ahead of schedule with outstanding efficacy and safety data, showing clear superiority or safety advantages over heparin and citrate. The FDA grants rapid PMA approval in 2027. CorMedix exercises its right of first negotiation and acquires Talphera at a significant premium, or Talphera successfully launches Niyad, capturing a major share of the 57% of the CRRT market that currently uses citrate or no anticoagulant due to safety concerns.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Niyad holds FDA Breakthrough Device Designation, addressing a clear unmet need in the US CRRT market where there are currently no FDA-approved regional anticoagulants.
Strategic validation and financial backing from CorMedix Inc., including an exclusive right of first negotiation for acquisition, which provides a clear path to liquidity.
Rebuilt balance sheet with $21.1 million in cash and investments as of March 31, 2026, plus $16 million in conditional future financing tranches to fund operations through potential PMA approval.

Key Investment Risks

Clinical trial risk: The NEPHRO CRRT study may fail to meet its endpoints or experience safety issues.
Regulatory risk: The FDA may delay or deny PMA approval for Niyad.
Financial risk: As a clinical-stage company with minimal revenues ($28K in FY2025), Talphera is dependent on external financing and milestone-based tranches to sustain operations.

Thesis Invalidation Triggers

Failure of the NEPHRO CRRT study to meet its primary safety or efficacy endpoints.
Inability to close the remaining $16 million in conditional financing tranches due to missed milestones.
CorMedix declining to enter negotiations or acquire the company following the release of Phase 3 data.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.